In this study, people receive either the vitamin D3 drops or placebo, and the care team follows their progress over time. The study looks at what happens during the hospital stay and after discharge, including survival, time in intensive care, time in the hospital, and later health problems such as infections, falls, fractures, and kidney stones. It also checks for possible side effects of high vitamin D, such as hypercalcemia, which means too much calcium in the blood.

During the study, participants will be given either sodium hydrogen carbonate or a comparison solution containing electrolytes, such as sodium chloride, calcium chloride dihydrate, potassium chloride, or magnesium chloride hexahydrate. These comparison solutions include options like Jonosteril Infusionslösung, Sterofundin ISO Infusionslösung, and Ringer-Infusionslösung B. Braun. The study monitors various health outcomes over a 90-day period, including the need for kidney replacement therapy, which refers to treatments like dialysis that perform the work of the kidneys, and changes in creatinine levels, a substance in the blood used to measure how well the kidneys are functioning.

The purpose of this study is to investigate whether the duration of antibiotic infusion affects how well the medication reaches and maintains effective levels in the bloodstream of children. Participants will be randomly assigned to receive their prescribed antibiotic either through the extended infusion method or the shorter intermittent infusion method. During the study, blood samples will be collected to measure the concentration of the antibiotic in the blood, and various indicators of infection and recovery will be monitored.

The study will track several outcomes including how quickly infection markers in the blood return to normal, how long patients need to stay in the intensive care unit, and whether any side effects occur. This research could help determine the most effective way to administer these important antibiotics to critically ill children.

Several types of fluid solutions will be used in the study. These include a solution with sodium chloride alone, a combination of sodium chloride and glucose monohydrate (a form of sugar), a solution with just glucose monohydrate, and a more complex solution called Plasmalyte A, which contains a mix of substances like magnesium chloride hexahydrate, potassium chloride, sodium acetate trihydrate, and sodium gluconate. These solutions are given to patients through an intravenous (IV) line, which means they are delivered directly into the bloodstream.

The purpose of the study is to determine if reducing the salt content in these fluids can improve patient outcomes. The trial will monitor various health indicators over a period of time, including the number of days patients are alive without needing life support, as well as occurrences of conditions like low or high sodium levels, fluid retention, and kidney injury. The study will also track the use of mechanical ventilation and the overall length of stay in the ICU. The trial is expected to continue until 2028, with the goal of providing valuable insights into the best fluid management strategies for critically ill patients.

The purpose of the study is to understand how the body absorbs and processes Midazolam when given by these two different methods. This will help determine which method might be more effective or comfortable for patients. The study will involve adult men and women who are terminally ill and have a life expectancy of less than one month. Participants will receive either the subcutaneous or intravenous form of Midazolam to help manage their symptoms.

Throughout the study, researchers will monitor how the medication is absorbed in the body and any changes in symptoms or side effects. This includes checking for any discomfort at the injection site and changes in breathing or oxygen levels. The study aims to provide valuable information that could improve symptom management for terminally ill patients in the future.

The purpose of the study is to see which sedation method allows patients to be free from mechanical ventilation for more days within a 28-day period. Patients in this study are expected to need mechanical ventilation for more than 48 hours. The study will also look at other factors, such as the number of days patients spend in the intensive care unit (ICU), the time it takes for patients to be taken off the ventilator after stopping sedation, and the overall well-being of patients after they leave the hospital.

Throughout the study, researchers will monitor various aspects of the patients’ health, including their mental state using a scale called the RASS (Richmond Agitation-Sedation Scale), and check for any signs of delirium, which is a state of confusion. They will also assess if patients experience anxiety, depression, or post-traumatic stress disorder after their hospital stay. The study aims to provide valuable information on the best sedation practices for critically ill patients who need mechanical ventilation.

Participants in the study will receive either the testosterone gel or the placebo gel for a period of up to 28 days. The study will monitor the physical performance of participants at different intervals: three months, six months, and one year after ICU admission. This will include tests like the six-minute walk distance test, which measures how far a person can walk in six minutes. The study will also look at muscle strength, muscle mass, and overall functional status over time. Additionally, the safety of the testosterone gel will be assessed by monitoring for any side effects such as high blood pressure, cardiovascular events, or changes in blood cell counts.

The purpose of this study is to determine if early administration of testosterone gel can help improve recovery and physical performance in critically ill patients. The trial will also track other outcomes such as the number of days patients are free from ventilation, the length of stay in the ICU and hospital, and mortality rates. The study is expected to continue until July 2027, with the goal of providing valuable insights into the potential benefits of testosterone treatment in this patient group.

The purpose of the study is to develop an optimized dosing regimen of ceftazidime-avibactam for these patients. Participants in the study will receive the medication intravenously, which means it will be given directly into a vein. The study will monitor how the medication is processed in the body and how well it reaches the desired levels to fight infections effectively. This will help in understanding the best way to dose the medication for patients who are receiving CRRT.

The study will take place over a period of time, and researchers will collect information on how the medication behaves in the body, known as pharmacokinetics. This information will be used to create a model that helps determine the best dosing strategy for ceftazidime-avibactam in critically ill patients. The ultimate goal is to ensure that patients receive the most effective treatment possible while minimizing any potential side effects.

The treatment being studied includes the use of a medication called amikacin sulfate, which is an antibiotic that belongs to a group of drugs known as aminoglycosides. Antibiotics are medicines used to treat infections caused by bacteria. In this study, amikacin sulfate is given to patients through a vein, a method known as intravenous use. The purpose of the study is to see if adding amikacin sulfate to the usual antibiotic treatment can improve the outcomes for these patients. Additionally, the study is looking at whether not using protective isolation, a practice where patients are kept separate to prevent infections, affects the patients’ recovery.

The study will follow patients for a period of time to observe their health outcomes, including survival rates and any side effects they may experience. Researchers will also monitor the occurrence of kidney problems, hearing loss, and other serious health events. The goal is to understand if the combination of treatments can help reduce the risk of death and improve recovery in patients with sepsis and neutropenia. The study is expected to continue until 2025, and the findings will help guide future treatments for critically ill patients with these conditions.

The purpose of the study is to determine whether using furosemide for fluid removal is more beneficial than allowing the body to remove fluid on its own. Participants in the study will receive either furosemide or a placebo through an intravenous infusion, which means the medication is given directly into a vein. The study will monitor the number of days patients are alive and out of the hospital, as well as other important health outcomes, over a period of 90 days and up to one year.

Throughout the study, researchers will also look at other factors such as overall survival rates, the number of days patients can live without needing life support, and any serious side effects. Additionally, the study will assess the quality of life and cognitive function of participants after one year. This research aims to provide valuable insights into the management of fluid overload in ICU patients and improve treatment strategies for this condition.

Participants in the study will receive either the combination of Hydrocortisone Hemisuccinate and Fludrocortisone Acetate or a placebo. The treatment will be administered over a period of up to seven days. The study will monitor the number of days participants are alive and free from the need for a ventilator or vasopressors, which are medications that help maintain blood pressure, within 30 days after starting the treatment. The goal is to see if the combination of these medications can help improve recovery in patients with CIRCI.

In addition to the primary focus, the study will also look at other outcomes, such as the length of stay in the intensive care unit (ICU) and hospital, the rate of re-admission to the ICU, and overall survival rates at different time points. The study will also assess the safety of the treatment and any potential side effects. This research is important for understanding how to better support critically ill patients who may have insufficient levels of corticosteroids in their bodies.

The purpose of this research is to examine how well these antibiotics work when their dosing is guided by a special calculation method in critically ill children. The study will use precise measurements to determine if the right amount of medicine is reaching the infection. Each participant will receive one of the three antibiotics for up to 8 weeks of treatment.

During the study, doctors will monitor how the antibiotics work in the body by taking blood samples at different times. This helps ensure that enough medicine is present in the body to fight the infection effectively. The treatment approach being studied aims to provide more accurate dosing of these important medications for young patients who are seriously ill.

The purpose of the study is to determine if using Noradrenaline Tartrate before the intubation procedure can reduce the risk of cardiovascular collapse in critically ill adults. Participants in the study will receive either the medication or a placebo before undergoing tracheal intubation. The study will monitor the participants’ blood pressure and heart function during and after the procedure to assess the effectiveness of the treatment.

The trial aims to provide valuable information on whether pre-emptive treatment with Noradrenaline Tartrate can improve outcomes for patients undergoing tracheal intubation due to critical illness. The study is expected to continue until October 2024, with the goal of enhancing the safety and effectiveness of medical procedures for critically ill patients.

The purpose of the study is to determine if epoetin alfa can help reduce the risk of death and severe disability in these patients over a period of six months. Epoetin alfa is a medication that is usually given as an injection and is known to help the body produce more red blood cells. In this trial, it is being compared to a placebo, which is a substance with no active medication, to see if it has a beneficial effect on the patients’ recovery.

Participants in the study will receive either epoetin alfa or a placebo while they are in the intensive care unit (ICU). The study will monitor their health outcomes over six months to assess the impact of the treatment. The main focus will be on whether the treatment helps reduce mortality and severe disability, as well as other health outcomes like survival rates and the occurrence of certain medical events. The trial is expected to continue until the end of 2025.

The main goal of the study is to evaluate the impact of using Dexmedetomidine as a primary sedative on the survival of patients over a period of 90 days. The study will also look at other important factors, such as the number of days patients are alive without experiencing coma or delirium, the number of days they are free from the ventilator, and any major kidney problems that may occur. Additionally, the study will assess how long patients need mechanical ventilation and their length of stay in the hospital.

The trial is expected to run until December 2025, with the recruitment of participants having started in August 2023. The findings from this study could help improve the care and treatment of older patients who are critically ill and require mechanical ventilation.

Participants in the study will receive vancomycin through an infusion, which means the medication is delivered directly into the bloodstream. The study will use a special tool to help doctors adjust the dose of vancomycin to keep it within a target range for most of the treatment period. This approach is intended to improve the effectiveness of the treatment and reduce the risk of side effects.

The study will monitor how well patients stay within the desired range of vancomycin levels in their blood. It will also look at other factors, such as how long patients stay in the hospital, their overall recovery, and any potential side effects like kidney problems. The goal is to find the best way to use vancomycin to treat serious infections in critically ill patients effectively and safely.

During the study, patients will receive one of the antibiotics mentioned above. The treatment will be given through a vein, which is known as intravenous administration. The study will observe how the antibiotics are processed in the body and how this affects the patient’s recovery. The study will also compare the outcomes of patients who receive regular monitoring of antibiotic levels with those who do not. This will help determine if monitoring can improve the effectiveness of the treatment.

The study will track various health indicators, such as the number of days patients spend in the ICU, the duration of hospital stays, and the need for mechanical ventilation. It will also monitor the presence of fever and certain biomarkers, which are substances in the body that can indicate how well the treatment is working. The study aims to provide valuable insights into the best ways to use antibiotics in critically ill patients to improve their chances of recovery.

Participants in the study will receive either the fish oil-based treatment or a placebo. The study will monitor the occurrence of atrial fibrillation for up to seven days after surgery. Other aspects of recovery, such as the time it takes to leave the hospital and overall survival, will also be observed. The study aims to enhance recovery and improve outcomes for patients who are at high risk during heart surgery.

The trial will take place over a period of time, with participants being closely monitored for any changes in their health. The study will also look at various factors like the length of stay in the hospital, the need for additional medical support, and any complications that may arise. The goal is to gather information that could lead to better care and recovery for patients undergoing complex heart surgeries.